search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Consequences of suboptimal glucocorticoid replacement therapy in Addison’s disease; The metabolic syndrome and QoL.


- candidate number6635
- NTR NumberNTR2062
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR22-okt-2009
- Secondary IDsABR-30390 CCMO
- Public TitleConsequences of suboptimal glucocorticoid replacement therapy in Addison’s disease; The metabolic syndrome and QoL.
- Scientific TitleConsequences of suboptimal glucocorticoid replacement therapy in Addison’s disease; The metabolic syndrome and QoL.
- ACRONYM
- hypothesis1. Dutch patients with Addison's disease treated with suboptimal glucocorticoid replacement therapy have a reduced QoL;
2. Prevalence of the metabolic syndrome is higher among patients with Addison's disease treated with suboptimal glucocorticoid replacement therapy compared to healthy controls.
- Healt Condition(s) or Problem(s) studiedMetabolic syndrome, Addison's disease, Quality of life, Glucocorticoid receptor polymorfism
- Inclusion criteriaPatients with primary adrenal insufficiency in the age of 18-70 years.
- Exclusion criteria1. Intercurrent infectious or serious disease;
2. Use of other oral medications containing glucocorticoids;
3. High dose inhalation glucocorticoids (>800 microgram a day);
4. Pregnancy.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-jan-2010
- planned closingdate9-jan-2010
- Target number of participants120
- Interventions1. Questionnaires;
2. Measurement of blood pressure, weight, height, waist circumference;
3. A fasting blood sample.
- Primary outcome1. Presence of metabolic syndrome (3 or more abnormalities of waist circumference, blood pressure, triglycerides, HDL-cholesterol, glucose);
2. Quality of life score.
- Secondary outcomePresence of glucocorticoid receptor polymorfisms in relation to the metabolic syndrome and QoL.
- TimepointsCross sectional.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES L.C.C.J. Smans
- CONTACT for SCIENTIFIC QUERIES L.C.C.J. Smans
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Utrecht (UMCU)
- PublicationsN/A
- Brief summaryIntroduction:
Patients with Addison’s disease are treated with glucocorticoid replacement therapy (GRT). In spite of replacement therapy, patients with Addison’s disease experience a lot of complaints. Glucocorticoids are essential for life but in excess they produce many unwanted effects on metabolism, cardiovascular, musculoskeletal and immune function. Glucocorticoid side effects are probably dose dependent. The serious adverse effects of high dose GRT are reported in large trials in patients with different diseases including, asthma, SLE and rheumatoid arthritis. The evidence on which to support clear recommendations about toxicity of low dose glucocorticoids is weak. Patients with Addison’s disease are treated with long term low dose GRT. The effects of low dose GRT on quality of life and metabolism in this patient group are not clear.

Objective:
Assess the prevalence of the metabolic syndrome and quality of life in patients with Addison’s disease treated with low dose GRT.

Study design:
Case-control observational study.

Study population:
Patients with primary adrenal insufficiency on a stable replacement therapy with glucocorticoids will be included in this study and results will be compared to data of age and sex matched controls.

Endpoints:
Quality of life and prevalence of the metabolic syndrome.

Inconvenience, risks and advantages:
Blood samples will be obtained and participants have to complete questionnaires. There is a small risk of infection or haematoma formation when obtaining the blood sample. An advantage of participating in this study is treatment of risk factors if the metabolic syndrome is diagnosed.
- Main changes (audit trail)
- RECORD22-okt-2009 - 31-okt-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl